Over the last few weeks we initiated the calibration of lab conditions to ensure consistency and accuracy in our preclinical studies. As part of this process, we conducted initial testing of TRAABA24 encapsulated in a lipid nanoparticle formulation across two pseudomyxoma peritonei (PMP) cell lines.

The preliminary results clearly highlight the advantages of nanoparticle-based drug delivery, demonstrating a significant and differentiated impact on cell survival and proliferation. Notably, TRAABA24 exhibited potent activity at just one-tenth (1/10) the dose of the Mitomycin C positive control, reinforcing the therapeutic potential of our formulation. These findings provide further support for TRAABA24’s ability to target PMP through a distinct mechanism compared to the current standard of care.

The images below offer a firsthand glimpse into our progress.